MMRGlobal Enters Eighth Year Ready to Capitalize on Patient Engagement and Meaningful Use Regulations Mandating Personal Health

MMRGlobal Enters Eighth Year Ready to Capitalize on Patient Engagement and 
Meaningful Use Regulations Mandating Personal Health
LOS ANGELES, CA -- (Marketwired) -- 04/02/13 --  MMRGlobal, Inc.
(OTCQB: MMRF), a leading provider of Personal Health Records
("PHRs"), MyEsafeDepositBox storage solutions and electronic document
management and imaging systems for healthcare professionals, today
announced that it filed its Annual Report on Form 10-K for the period
ended December 31, 2012 with the U.S. Securities and Exchange
Commission on April 1, 2013. The Company reported a 21% reduction in
operating expenses, a 24.9% reduction in G&A, a 15.1% reduction in
sales and marketing expenses, a 24.3% reduction in technology and
development costs, an 81% reduction in interest and finance charges,
resulting in an overall reduction of net loss from $8,884,427 in 2011
to $5,902,503 in 2012, or 33.6%. The results did not include a
backlog in revenues from signed agreements which represent more than
$40 million in future revenues not including revenue from license
agreements pertaining to the Company's Health Information Technology
patents (the "MMR IP").  
"Eight years ago, waiting was not an option. After watching the
deregulation of AT&T and the collapse of the Bell system, I believed
that the day would come when, based on the agendas set forth by the
Bush and Obama administrations to force interoperability and patient
engagement through the use of computerized medical records, the
market would demand an efficient cost-effective way to deliver a
standardized Personal Health Record to consumers. Based on
expenditures of more than $40 million, and as a result of government
regulations mandating that patients be provided timely online access
to their personal health information under the HITECH Act, we believe
our time has come. MMR is now in the process of licensing and
delivering its patented Personal Health Record to the global
healthcare market," said Robert H. Lorsch, MMRGlobal Chairman and
Until now, the Company has worked hard to drive consumers to use its
products and services. Due to macro-economic and changing government
conditions, consumers and healthcare professionals are being driven
to technology that takes advantage of M
MR's IP.  
MMR is continuing its efforts to license to hospitals, physicians,
ambulatory surgical centers, laboratory systems, pharmacies and
vendors of selected health IT products and services. As part of this
effort, it is actively working with two of the ten leading EHR
vendors who earned 66 percent of all Medicare EHR Incentive Payments
for their customers from May 2011 to September 2012. The Company is
also continuing efforts to expand its significant patent portfolio
with continuation applications and additional pending applications on
file around the world. In the U.S., the MMR has seven U.S. patents
issued under the headings, "Method and System for Providing Online
Medical Records" and "Method and System for Providing Online
Records," with more than 400 surrounding claims, as well as patents
issued, and/or pending in numerous countries around the world,
including Australia, Singapore, New Zealand, Mexico, Japan, Canada,
Hong Kong, South Korea, Israel, and Europe. A special report
published on January 22, 2013 concluded that the range of value for
the Company's U.S. health IT patents could reach between $600 million
to $1.1 billion in revenue based on what is described as conservative
estimates of a market projected to reach a GDP value of $19 billion.
(For additional information see 
The Company is also continuing its global initiative in China.
Current documentation pertaining to the Henan Government Medical
project will include design documentation from MMR's Personal Health
MMR has also filed patent infringement claims against Walgreen Co.,
titled MyMedicalRecords, Inc. v. Walgreen Co., United States District
Court, Central District of California, Case No. CV 13-00631 ODW (SHx)
and others in which it is engaged in active settlement discussions.
MMR plans on filing similar actions this quarter directed toward PHR
providers, hospitals, and laboratory services providers, among
others. In addition, the Company is continuing to investigate
possible infringement of MMR's intellectual property in Australia and
by vendors of health IT products and services in Singapore.  
MyMedicalRecords, Inc. has also completed required arbitration
proceedings with Surgery Center Management, LLC ("SCM") and is
continuing its efforts to collect $30 million in license fees under
the Settlement and Patent License Agreement for use of MMR's health
information technology patents. $10 million of such fees are already
past due. MMR has also filed a motion for sanctions for costs and
expenses for what it believes to be caused by meritless appeals.  
On the biotech front, the Company received additional patents in 2012
entitled "Antibodies and Methods for Making and Using Them" and
"Method and Composition for Altering a B Cell Mediated Pathology"
from the Mexican Industrial Property Institute. The first patent has
special significance because it represents an anti-CD20 monoclonal
antibody patent which marks the first such approval for protection of
the Company's specific antibodies that have particular utility in
fighting cancers. Patents for the Company's antibodies are also
pending in a number of additional countries including the United
States, Australia, Brazil, Canada, China, Hong Kong, India, Europe,
Japan and Korea. The second Mexican patent relates to methods of
manufacturing compositions for B-cell vaccines used in the fight
against lymphoma and potentially other forms of cancer and is similar
to those manufacturing patents issued in the U.S., including U.S.
Patent No. 8,114,404 and 8,113,486 issued in the first quarter of
2012, and Singapore, and is pending in various other countries of
commercial interest. Subsequently, in January 2013, the Company
announced approval of its European Union patent also directed at
"Method and Composition for Altering a B Cell Mediated Pathology,"
protecting the manufacturing of our B-cell vaccines (which was under
appeal in Europe for some time). This issued patent is currently
undergoing the process of validating the patent in numerous countries
including the United Kingdom, France, Germany, Switzerland, Spain,
Italy, the Netherlands, Denmark, Sweden, Finland, Ireland and
In an effort to continue exploiting its biotech assets, the Company
is currently looking at the possibility of entering into a
transaction involving a new cancer drug in the field of Epigenetics,
which was discussed in the April 1st issue of Time Magazine. Biotech
ventures in publicly traded companies can carry significant
valuations such as MAP Pharmaceuticals, Inc., which had no revenue,
yet was sold last month to Allergan for nearly one billion dollars.
Management believes that the Company's valuation should include the
value of all its health IT and biotech intellectual property, similar
to other IP-holding companies that have invented, license and sell
their IP. 
About MMRGlobal
 MMRGlobal, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit
box storage solutions, serving consumers, healthcare professionals,
employers, insurance companies, financial institutions, retail
pharmacies, and profe
ssional organizations and affinity groups. The
MyMedicalRecords PHR enables individuals and families to access their
medical records and other important documents, such as birth
certificates, passports, insurance policies and wills, anytime from
anywhere using the Internet. MyMedicalRecords is built on
proprietary, patented technologies to allow documents, images and
voicemail messages to be transmitted and stored in the system using a
variety of methods, including fax, phone, or file upload without
relying on any specific electronic medical record platform to
populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and
cost-effective solution to digitizing paper-based medical records and
sharing them with patients through an integrated patient portal.
Through its merger with Favrille, Inc. in January 2009, the Company
acquired intellectual property biotech assets that include anti-CD20
antibodies and data and samples from its FavId(TM)/Specifid(TM)
vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's
lymphoma. To learn more about MMRGlobal, Inc. visit View demos and video tutorials of the Company's
products and services at 
Forward-Looking Statements 
 All statements in this press release
that are not strictly historical in nature, including, without
limitation, intellectual property enforcement actions, infringement
claims or litigation, intellectual property licenses, and future
performance, management's expectations, beliefs, intentions,
estimates or projections, constitute "forward-looking statements."
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from historical results or from
any results expressed or implied by such forward-looking statements.
Some can be identified by the use of words (and their derivations)
such as "need," "possibility," "potential," "intend," "offer,"
"development," "if," "negotiate," "when," "begun," "believe,"
"achieve," "will," "estimate," "expect," "maintain," "plan," and
"continue," or the negative of these words. Actual outcomes and
results of operations and the timing of selected events may differ
materially from the results predicted, and any reported results
should not be considered as an indication of future performance. Such
statements are necessarily based on assumptions and estimates and are
subject to various risks and uncertainties, including those relating
to the possible invalidity of the underlying assumptions and
estimates and possible changes or developments in economic, business,
industry, market, legal and regulatory circumstances and conditions
and actions taken or omitted to be taken by third parties, including
customers, suppliers, business partners, potential licensees,
competitors and legislative, judicial and other governmental
authorities and officials. Factors that could cause or contribute to
such differences include, but are not limited to: unexpected outcomes
with respect to intellectual property enforcement actions, claims of
intellectual property infringement and general intellectual property
litigation; our ability to maintain, develop, monetize and protect
our patent portfolio for both the Company's health IT and
biotechnology intellectual property assets in the U.S. and
internationally; the timing of milestone payments in connection with
licensing our intellectual property; our ability to establish and
maintain strategic relationships; changes in our relationships with
our licensees; the risk the Company's products are not adopted or
viewed favorably by the healthcare community and consumer retail
market; business prospects, results of operations or financial
condition; risks related to the current uncertainty and instability
in financial and lending markets, including global economic
uncertainties; the timing and volume of sales and installations; the
length of sales cycles and the installation process; the market's
acceptance of new product and service introductions; competitive
product offerings and promotions; changes in government laws and
regulations including the 2009 HITECH Act and changes in Meaningful
Use and the 2010 Affordable Care Act; future changes in tax
legislation and initiatives in the healthcare industry; undetected
errors in our products; the possibility of interruption at our data
centers; risks related to third party vendors; risks related to
obtaining and integrating third-party licensed technology; risks
related to a security breach by third parties; risks associated with
recruitment and retention of key personnel; other litigation matters;
uncertainties associated with doing business internationally across
borders and territories; and additional risks discussed in the
Company's filings with the Securities and Exchange Commission,
including disclosures about the Company's relationship with the
Michael Bass Group since 2009. Additional information is set forth in
the Company's Annual Report on Form 10-K for the year ended December
31, 2012. The Company is providing this information as of the date of
this release and, except as required by applicable law, does not
undertake any obligation to update any forward-looking statements
contained in this release as a result of new information, future
events or otherwise.   
Michael Selsman
Public Communications Co.
(310) 922-7033 
Press spacebar to pause and continue. Press esc to stop.